Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy.

Secondary outcome of OS did not reach statistical significance, though hazard ratio showed mortality reduction in the trastuzumab arm (HR 0.41) [ 26 •].

also in 111,027 other papers